From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Exenatide trials with results
69 trials, 270,101 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| ON TARGET DMComparison of Type 2 Diabetes Pharmacotherapy Regimens | Exenatide | 241,981 | Incidence of 3-point Major Adverse Cardiovascular Events (MACE) (Participants), 2.5 years. SU Initiators: 11,348; DPP4 Initiators: 393; SGLT2i Initiators: 424; GLP-1RA Initiators: 296. |
| NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | Exenatide | 14,752 | Primary Efficacy Outcome MACE Events (Participants), Time to first event. Information collected during study period (anticipated to be up to 7.5 years).. Placebo: 905; Exenatide Once Weekly: 839. |
| NCT00960661A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes | Exenatide | 1,036 | Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 (percent of hemoglobin), Baseline, 30 weeks. Exenatide (BET): -1.13; Insulin Lispro (BBT): -1.10. |
| NCT00359762Exenatide Versus Glimepiride in Patients With Type 2 Diabetes | Exenatide | 1,029 | Time to Treatment Failure (week), Baseline to end of Period II (up to 4.5 years). Exen + Met: 180.0; Glim + Met: 142.1. |
| NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Exenatide | 820 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.53; Metformin: -1.48; Pioglitazone: -1.63; Sitagliptin: -1.15. |
| NCT02229396Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo | Exenatide | 695 | Change in HbA1c From Baseline to Week 28 (% HbA1c), Baseline to Week 28. Dapagliflozin + Placebo: -1.39; Exenatide + Dapagliflozin: -1.98; Exenatide + Placebo: -1.60. |
| NCT00917267A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects | Exenatide | 691 | Change in HbA1c From Baseline to Week 26. (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.43; Exenatide Twice Daily: -1.12. |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide | 639 | Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (percentage of hemoglobin), Baseline, Week 24. Lixisenatide: -0.79; Exenatide: -0.96. |
| NCT00082381Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin | Exenatide | 551 | See the trial's page: several measures or groups. |
| NCT00637273A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) | Exenatide | 514 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Day 1, Week 26. Exenatide Once Weekly: -1.55; Sitagliptin: -0.92; Pioglitazone: -1.23. |
| NCT00082407Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Exenatide | 505 | See the trial's page: several measures or groups. |
| NCT00434954Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes | Exenatide | 494 | Change in Glycosylated Hemoglobin (HbA1c) (Percentage of glycosylated hemoglobin), Baseline and 26 weeks. Exenatide Twice Daily: -1.00; Premixed Insulin Aspart Twice Daily: -1.14. |
| NCT00641056Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) | Exenatide | 467 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.47; Insulin Glargine: -1.31. |
| NCT02229383Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus | Exenatide | 464 | Change in HbA1c From Baseline to Week 28 (Percentage of HbA1c), Baseline to Week 28. Exenatide: -0.96; Placebo: -0.22. |
| NCT00935532Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus | Exenatide | 427 | Change in HbA1c From Baseline to Endpoint (Week 26) (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.11; Insulin Glargine: -0.68. |
| DURATION-NEO-1Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes | Exenatide | 377 | Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 (Percentage of total hemoglobin), Baseline to Week 28. Experimental: Exenatide QWS Suspension: -1.39; Active Comparator: Exenatide BID: -1.02. |
| DURATION-NEO-2Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus | Exenatide | 365 | Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 (percentage of total hemoglobin), Baseline to Week 28. Experimental: Exenatide: -1.13; Active Comparator: Sitagliptin: -0.75; Placebo Comparator: Placebo: -0.40. |
| NCT00560417Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Exenatide | 339 | See the trial's page: several measures or groups. |
| NCT00308139Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) | Exenatide | 303 | Change in HbA1c From Baseline to Week 30 (percentage of total hemoglobin), Day -3, Week 30. Exenatide Once Weekly: -1.87; Exenatide Twice Daily: -1.54. |
| NCT00765817Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | Exenatide | 261 | Change in Glycosylated Hemoglobin (HbA1c) (percentage of hemoglobin), baseline and 30 weeks. Exenatide Arm: -1.71; Placebo Arm: -1.00. |
| NCT00877890A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Exenatide | 254 | Change in HbA1c From Baseline to Week 24 (percentage of total hemoglobin), Day 1, Week 24. Exenatide Once Weekly: -1.57; Exenatide Twice Daily: -0.90. |
| NCT00360334A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients | Exenatide | 235 | Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) (percentage of participants), 26 weeks. Exenatide: 53.4; Insulin Glargine: 19.8. |
| NCT01003184Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Exenatide | 222 | Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26) (Percentage), Baseline, Week 26. Exenatide Once Weekly: 44.1; Insulin Detemir: 11.4. |
| NCT00375492Effect on Weight Loss of Exenatide Versus Placebo | Exenatide | 196 | Change From Baseline in Body Weight (kg), Baseline, Week 24. Group A (Exenatide): -6.16; Group B (Placebo): -3.97. |
| NCT00577824Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Exenatide | 181 | Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 (Percentage of hemoglobin), baseline, 24 weeks. 5mcg Exenatide BID: -1.34; 10mcg Exenatide BID: -1.62; Placebo BID: -0.28. |
| NCT00603239Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin | Exenatide | 165 | Change in Glycosylated Hemoglobin (HbA1c) (Percentage), baseline and 26 weeks. Exenatide Twice Daily (BID): -0.84; Placebo: -0.10. |
| NCT00856609The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | Exenatide | 150 | Energy Intake (kcal/day), Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention). Exenatide: 1016.1; Placebo: 245.1. |
| NCT00135330An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus | Exenatide | 137 | See the trial's page: several measures or groups. |
| NCT00753896Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin | Exenatide | 134 | See the trial's page: several measures or groups. |
| NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes | Exenatide | 122 | Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 (percentage (%HbA1c)), Baseline (Day 1) and Week 28. Total Exenatide Twice Daily (EBID): 0.11; Placebo: 0.38. |
| NCT02635386EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Exenatide | 119 | Oral Disposition (Insulin Sensitivity-insulin Secretion) Index (index score), 24 weeks of treatment. Exenatide Once Weekly (EQW ): 471; Dapagliflozin (DAPA): 311; EQW Plus DAPA: 503; Dapagliflozin Plus Glucophage (MET ER): 395; Phentermine /Topiramate (PHEN/ TPM) ER: 545. |
| NCT02496611Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity | Exenatide | 100 | Body Mass Index (percentage (body mass index)), 52 weeks. Weight Loss Maintenance Without Pharmacotherapy: 10.1; Weight Loss Maintenance With Pharmacotherapy: 4.6. |
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide | 92 | Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57. |
| NCT01554618Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes | Exenatide | 84 | Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) (percentage (% HbA1c)), Baseline (Week 0) and Week 24. Controlled Assessment Period - Exenatide: -0.36; Controlled Assessment Period - Placebo: 0.49. |
| NCT02975297Exenatide Once Weekly for Smoking Cessation | Exenatide | 84 | Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm (Participants), 6 weeks. Exenatide Plus NRT Plus Counseling: 19; Placebo Plus NRT Plus Counseling: 11. |
| NCT01928329A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes | Exenatide | 79 | Change From Baseline in HbA1c Levels (mmol/mol), 6 months. Exenatide (Bydureon): -0.12; Placebo: 0.11. |
| NCT01181986The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes | Exenatide | 76 | Reactive Hyperemia Index (RHI) (ratio), 0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2). Exenatide (Subs-study 1): 1.90; Placebo (Sub-study 1): 1.79; Saline+Exenatide (Sub-study 2): 2.24; Saline+Placebo (Sub-study 2): 1.95; Exendin-9+Exenatide (Sub-study 2): 1.99. |
| NCT02417142Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia | Exenatide | 70 | See the trial's page: several measures or groups. |
| NCT02962492An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes | Exenatide | 70 | Change in Beta-hydroxybutyrate Levels in Blood (mM), 12 weeks. Placebo Arm:: -0.23; Dapagliflozin Arm:: 0.63; Exenatide Extended Release Arm:: 0.24; Exenatide Extended Release & Dapagliflozin Arm:: 0.31. |
| NCT00097500Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes | Exenatide | 69 | Beta-cell Function After 52 Weeks of Therapy (ratio), Baseline (week -2) and 52 weeks. Exenatide Arm: 2.89; Insulin Glargine Arm: 1.15. |
| NCT00516048An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes | Exenatide | 58 | See the trial's page: several measures or groups. |
| NCT02251431Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome | Exenatide | 57 | See the trial's page: several measures or groups. |
| NCT01255163A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease | Exenatide | 57 | Number of Participants With Incidence of Nausea (Participants), 18 months. Exendin-4: 5; Placebo: 0. |
| NCT00516074A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes | Exenatide | 54 | See the trial's page: several measures or groups. |
| NCT00546728The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes | Exenatide | 50 | Change in Reactive Hyperemic Index Over the 3-month Treatment Period (ratio), Change from baseline to 3 months. Exenatide: 0.01; Metformin: -0.17. |
| NCT00775684Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass | Exenatide | 47 | See the trial's page: several measures or groups. |
| PIO-EXEffect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function | Exenatide | 43 | Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight (kg), baseline and 6 months. PIOGLITAZONE: 5.5; EXENATIDE: 2.4; PIOGLITAZONE and EXNATIDE: 2.7. |
| ECHOEnergy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | Exenatide | 42 | Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². (percent change from baseline), From baseline to 36 weeks. Exenatide Once Weekly Extended-release: 1.7; Matching Placebo: 3.5. |
| NCT00456885The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women | Exenatide | 41 | Change in Weight (kilograms), 16 weeks after the beginning of each treatment. Exenatide: -2.49; Placebo: 0.43. |
| NCT00736229Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients | Exenatide | 40 | Median Glucose Values From Steady State Through 48 Hours or Until Discharge. (mg/dL), 1-48 hours. Exenatide: 132; Moderate: 127; Intensive: 105. |
| NCT01269047Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia | Exenatide | 37 | Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus. (mmol/L), 6 months. Acute Pramlintide + Insulin Group: 9.03; Acute Exenatide + Insulin Group: 8.4; Chronic Pramlintide + Insulin Group: 8.0; Chronic Exenatide + Insulin Group: 10.2; Insulin Monotherapy: 10.8. |
| NCT01237197Exenatide in Extreme Pediatric Obesity | Exenatide | 26 | Percent Change From Baseline in Body Mass Index at 3-months (percentage of change in BMI), Baseline and 3-months. Exenatide: -2.9; Placebo Injection: -0.15. |
| NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease | Exenatide | 24 | See the trial's page: several measures or groups. |
| NCT00679042Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol | Exenatide | 21 | See the trial's page: several measures or groups. |
| NCT02104739Effects of Antidiabetic Medications on the Postprandial State in Prediabetes | Exenatide | 21 | Monocyte NfkB Levels as Detected by Western Blotting (NfkB p65 arbitrary units), baseline. Exenatide: 62.79; Saxagliptin: 72.03; Placebo: 67.68; Exenatide Extended-release (ER): 84.19. |
| NCT01588418Acute Effect of Exenatide on Brain Glucose Metabolism | Exenatide | 15 | See the trial's page: several measures or groups. |
| 1981GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes | Exenatide | 15 | Change From Baseline in Urinary Albuminuria Levels (microgram/mg creatinine), baseline and 52 weeks. Exenatide Extended Release: -32; Placebo: -12. |
| IIH EVOLVEA Trial to Determine the Efficacy and Safety of Presendin in IIH | Exenatide | 14 | See the trial's page: several measures or groups. |
| NCT01269034New Onset Type 1 Diabetes: Role of Exenatide | Exenatide | 13 | See the trial's page: several measures or groups. |
| NCT00886626GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children | Exenatide | 12 | Change in Body Mass Index (BMI) (change in kg/m^2), 3-month. Exenatide: -0.9; Control: 0.84. |
| NCT00456300Role of Exenatide in Type 1 Diabetes | Exenatide | 11 | Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone (mmol*L/min), 0-120 minutes post-dose. Exenatide 1.25 mcg + Insulin: 49; Exenatide 2.5 mcg + Insulin: 44; Insulin Monotherapy: 379. |
| NCT01444898Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome | Exenatide | 10 | See the trial's page: several measures or groups. |
| NCT00566813Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression | Exenatide | 10 | Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation (participants), 15 months after the last transplant. Islet Cells: 4; Islet Cells + Etanercept + Exenatide: 5. |
| NCT03961256Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation | Exenatide | 9 | Progression From Prediabetes to Diabetes (Participants), 12 months after transplantation. Exenatide SR Intervention Group: 0; Standard of Care: 1. |
| NCT03645408The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers | Exenatide | 8 | Alcohol Consumption (standard drink units (SDUs)), 2 hours. Exenatide Injection: 0.93; Sham Injection (Placebo): 2.78. |
| NAFLDRole of Exenatide in NASH-a Pilot Study | Exenatide | 8 | See the trial's page: several measures or groups. |
| NCT01791465Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults | Exenatide | 6 | See the trial's page: several measures or groups. |
| NCT00799435Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure | Exenatide | 2 | See the trial's page: several measures or groups. |
| NCT00529204Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease | Exenatide | 1 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.